Results 111 to 120 of about 5,956,077 (339)

Drug tolerability versus drug safety

Journal of Dermatological Treatment, 2023
Stuti Prajapati, Rachel Tao, Steven R. Feldman   +2 more
openaire   +3 more sources

Therapeutic strategies for MMAE‐resistant bladder cancer through DPP4 inhibition

Molecular Oncology, EarlyView.
We established monomethyl auristatin E (MMAE)‐resistant bladder cancer (BC) cell lines by exposure to progressively increasing concentrations of MMAE in vitro. RNA sequencing showed DPP4 expression was increased in MMAE‐resistant BC cells. Both si‐DPP4 and the DPP4 inhibitor sitagliptin suppressed the viability of MMAE‐resistant BC cells.
Gang Li, Shuichi Tatarano, Hirofumi Yoshino, Saeki Saito, Mitsuhiko Tominaga, Junya Arima, Ikumi Fukuda, Takashi Sakaguchi, Ryosuke Matsushita, Yasutoshi Yamada, Hideki Enokida   +10 more
wiley   +1 more source

Phenotypic diversity drives paracrine drug tolerance

EMBO Molecular Medicine, 2017
Considerable clinical successes have been achieved in cancer treatment since the introduction of targeted therapies. However, almost inevitably tumors develop therapy resistance, which limits durable clinical responses. Tumors are often heterogeneous, and as a result, therapy‐resistant cells are present even before the start of treatment. Resistance is
Thomas Kuilman, Daniel S Peeper
openaire   +3 more sources

Combining antibody conjugates with cytotoxic and immune‐stimulating payloads maximizes anti‐cancer activity

Molecular Oncology, EarlyView.
Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang, Dong Jun Koo, Peter M. Tessier, Greg M. Thurber   +3 more
wiley   +1 more source

Genetic determinants of Mycobacterium tuberculosis adaptation and drug efficacy during stationary phase growth

Microbiology Spectrum
The adaptation of Mycobacterium tuberculosis (Mtb) to a slowly growing or nongrowing state in growth-limited conditions plays a crucial role for drug tolerance.
Xiao-Jie Shi, Kun-Xiong Shi, Fu Han, Li Wang, Xia Cai, Guo-Ping Zhao, Wei Sha, Liang-Dong Lyu   +7 more
doaj   +1 more source

Opiate Drug Seeking and Addiction: The Influence of Sucrose Consumption on the Acquisition and Expression of Morphine-induced Conditioned Place Preferences (CPP) [PDF]

, 2019
Sucrose intake may lead to changes in brain and behavior similar to the effects of abused drugs. For example, sucrose may agonize endogenous opiate systems and modulate opiate-seeking behavior.
Bakner, Lee, Berger, Isabel R., Senthithasan, Shareeta, Wolff, Stephanie   +3 more
core   +1 more source

Bacterial-derived exopolysaccharides enhance antifungal drug tolerance in a cross-kingdom oral biofilm

The ISME Journal, 2018
Fungal–bacterial interactions generate unique biofilms that cause many infections in humans. Candida albicans interact with Streptococcus mutans in dental biofilms associated with severe childhood tooth-decay, a prevalent pediatric oral disease.
Dongyeop Kim, Yuan Liu, Raphael I. Benhamou, H. Sanchez, A. Simón-Soro, Yong Li, G. Hwang, M. Fridman, D. Andes, H. Koo   +9 more
semanticscholar   +1 more source

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

Molecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat, Aslihan Kucuk, Omer Erdogan, Samed Ozer, Bensu Kozan, Tugba Cuceli, Erkan Gumus, Evrim Cevik, Ozge Cevik   +8 more
wiley   +1 more source

Development and validation of an ELISA-based method for determining neutralizing antibodies to pembrolizumab in human serum based on inhibition of the drug binding to its PD-1 target

Медицинская иммунология
Monoclonal antibodies (mAbs) are potentially able to trigger undesired humoral immune responses in the patients and develop ADA (anti-drug antibody) to the protein drugs.
A. M. Kudryashova, D. Yu. Grebenkin, M. Yu. Samsonov, O. V. Filon, V. A. Razzhivina, M. G. Chernobrovkin, O. V. Borisova   +6 more
doaj   +1 more source

The PI3Kδ inhibitor roginolisib (IOA‐244) preserves T‐cell function and activity

Molecular Oncology, EarlyView.
Identification of novel PI3K inhibitors with limited immune‐related adverse effects is highly sought after. We found that roginolisib and idelalisib inhibit chronic lymphocytic leukemia (CLL) cells and Treg suppressive functions to similar extents, but roginolisib affects cytotoxic T‐cell function and promotion of pro‐inflammatory T helper subsets to a
Elise Solli, Alessio Bevilacqua, Mathias Wenes, Denis Migliorini, Lars van der Veen, Sigrid S Skånland, Giusy Di Conza, Kjetil Taskén   +7 more
wiley   +1 more source